ICannabidiol (CBD)

I-Cannabidiol (i-CBD) yicandelo le-100% lokukhutshwa kwendalo okusebenzayo. Inayo i-anticonvulsant, sedative, hypnotic, antipsychotic, anti-inflammatory kunye neuroprotective iipropathi. Ngeenjongo zophando lwezenzululwazi kuphela, okanye njengezinto ezingafunekiyo zophuhliso lweemveliso ezisezantsi

Udidi: Akohlulwanga

inkcazelo

Cannabidiol (CBDumgubo Ulwazi loLwazi

igama	ICannabidiol kunye ne-CBD
Kubonakala	Mhlophe ukuya kumthubi okhanyayo we-crystalline powder
Iimeko	13956-29-1
IAsay	Iipesenti ezingama-99 (HPLC)
Umzimba	I-Soluble kwi-oyile, inyibilika kakhulu kwi-ethanol kunye ne-methanol, ayinyibiliki emanzini
Isisindo somzimba	314.46
Melt Point	62-63 ° C
I-Molecular Formula	C21H30O2
imvelaphi	Imveliso hemp
ukugcinwa Temp	Iqondo lobushushu kwigumbi, hlala umile kwaye kude nokukhanya
kwiBanga	KwiGrade yeBanga

Yintoni i Cannabidiol (CBD)?

I-Cannabidiol yaziwa ngokuba yi-CBD yenye yeekhemikhali ezingaphezu kwe-100 ezibizwa ngokuba zii-cannabinoids ezifumaneka kwisityalo se-cannabis okanye kwi-marijuana, i-Cannabis sativa. Ibekwe yodwa kwaye ihlanjululwe kwimifuno yeCannabis sativa, inezinto ezincinci kakhulu ze-THC. I-Tetrahydrocannabinol (i-THC) kunye ne-cannabidiol (i-CBD) zombini ziyasebenzisana ne-cannabinoid receptors kuwo wonke umzimba. Xa kuthelekiswa ne-9-THC, i-CBD ayinatyhefu njengoko ingabonisi ukusebenza kwengqondo. It has iintlungu, anti-ukudumba, antineoplastic kunye nemisebenzi chemopreventive. Emva kolawulo, i-cannabidiol (i-CBD) inesenzo sayo sokuchasana nokwanda, i-anti-angiogenic kunye ne-pro-apoptotic ngeendlela ngeendlela, ezinokuthi zingabandakanyi ukusayina nge-cannabinoid receptor 1 (CB1), CB2, okanye i-vanilloid receptor 1. uxinzelelo lwe-reticulum (ER) kunye nokuthintela ukubonakaliswa kwe-AKT / mTOR, ngokwenza oko kusebenze i-autophagy kunye nokukhuthaza i-apoptosis. Ukongeza, i-CBD inyusa ukuveliswa kweentlobo zeoksijini ezisebenzayo (iROS), ephinda inyuse iapoptosis. Le arhente ikwaphindaphinda ukubonakaliswa kwe-cell cell adhesion 1 (ICAM-1) kunye ne-tissue inhibitor ye-matrix metalloproteinases-1 (TIMP1) kunye nokunciphisa ukubonakaliswa kwe-inhibitor ye-DNA ebopha i-1 (ID-1). Oku kuthintela ukungena kweseli yomhlaza kunye ne-metastasis. I-CBD inokuphinda isebenze i-vanilloid yohlobo lwe-vanilloid yohlobo lwe-2 (TRPV2), enokuthi inyuse ukuthathwa kwee-cytotoxic arhente zomhlaza. Iziphumo ze-analgesic ze-CBD zixolelaniswe ngokubopha kwale arhente kunye nokusebenza kwe-CB1. I-Cannabidiol ixhaphake kakhulu kwisifo sokuxhuzula (isifo sokuwa) okanye i-dravet syndrome kunye nokukhululeka kwempawu zokumodareyitha ukuya kwiintlungu ezinzulu ze-neuropathic okanye ezinye iimeko ezibuhlungu, njengomhlaza. I-FDA yamkele i-CBD ngo-2018, kwaye kuphela kwonyango oluvunyiweyo lwe-FDA kwizigulana ezine-Lennox-Gastaut syndrome kunye ne-Dravet syndrome.

Cyonyaka (CBD) Indlela yokuSebenza

Indlela echanekileyo yokusebenza kwe-CBD kunye ne-THC ayiqondwa ngokupheleleyo ngoku. Nangona kunjalo, kuyaziwa ukuba i-CBD isebenza kwi-cannabinoid (CB) receptors yenkqubo ye-endocannabinoid, efumaneka kwiindawo ezininzi zomzimba, kubandakanya neepheripheral kunye neesistim zemithambo-luvo, kubandakanya nengqondo. Inkqubo ye-endocannabinoid ilawula iimpendulo zomzimba ezininzi kubandakanya iintlungu, inkumbulo, ukuthanda ukutya kunye nemood. Ngokukodwa, ii-receptors ze-CB1 zifumaneka ngaphakathi kweendlela zengqondo kunye nentambo yomqolo apho zinokuchaphazela i-analgesia ebangelwa yi-CBD kunye ne-anxiolysis, kunye ne-CB2 receptors ezinefuthe kwiiseli zomzimba, apho zinokuthi zichaphazele iinkqubo ezichaseneyo nokudumba . I-Cannabidiol (i-CBD) imetabolism yenzeka esibindini nasemathunjini. Ukutshaya i-bioavailability imalunga nama-31%. Ubomi besiqingatha se-CBD emva kokutshiza i-oromucosal iphakathi kwe-1.4 kunye ne-10.9 yeeyure, 2 kunye neentsuku ze-5 emva kokusetyenziswa komlomo okungapheliyo, kunye neeyure ezingama-31 emva kokutshaya. I-CBD iya kufezekisa uxinzelelo lweplasma phakathi kwe-0 kunye ne-4 hrs. I-CBD ibonakalisiwe ukuba isebenza njenge-allosteric modulator ye-CB1 receptor ye-cannabinoid, eyona nto ininzi ye-G-Protein Couple Receptor (GPCR) emzimbeni. Ummiselo we-Allosteric we-receptor ufezekiswa ngokumodareyitha komsebenzi we-receptor kwindawo esebenzayo eyahlukileyo ukusuka kwindawo ye-agonist okanye ye-antagonist binding. Iziphumo ezigwenxa zeemodyuli ze-CBD zibalulekile kunyango njengoko i-agonists ethe ngqo inikwe umda ziimpembelelo zabo zengqondo ngelixa abachasi ngokuthe ngqo benqunyelwe ziziphumo zabo zokudakumba.

Uyisebenzisa kanjani iCyonyaka (CBD)?

I-Cannabidiol (i-CBD) sisicatshulwa se-cannabis esenzelwe izibonelelo zempilo ezinokubakho. Ezona ndlela zimbini ziqhelekileyo zokuyithatha kwintengiso zezomlomo kunye nezihloko, njengee-capsules, i-tinctures, i-creams, kunye nokunye. Iioyile zeBBD zezona ndlela zithandwayo kakhulu zesicelo, yindlela efanelekileyo yokwenza i-cannabinoid. Ukuginya amathontsi aliqela eoyile ye-CBD isebenza njengeyona ndlela ilula kunye neyona ilungelelanisiweyo yokusebenzisa imolekyuli ngale ndlela. I-Cannabidiol inOKHUSELEKILEYO xa ithathwa ngomlomo okanye ifafazwe phantsi kolwimi ngokufanelekileyo. I-Cannabidiol ngeedosi ukuya kuthi ga kwi-300 mg yonke imihla ithathwe ngomlomo ngokukhuselekileyo ukuya kuthi ga kwiinyanga ezi-6. Amayeza aphezulu e-1200-1500 mg yonke imihla athathwe ngomlomo ngokukhuselekileyo ukuya kuthi ga kwiiveki ezi-4. Imveliso ye-cannabidiol yemithi (i-Epidiolex) ivunyiwe ukuba ithathwe ngomlomo ngeedosi ukuya kuthi ga kwi-25 mg / kg yonke imihla. Izitshizi zeCannabidiol ezisetyenziswa phantsi kolwimi zisetyenziswe kumthamo we-2.5 mg ukuya kuthi ga kwiiveki ezi-2. Umntu unokongeza ioyile ye-CBD kukutya nakwisiselo sokufihla incasa. Kodwa kwabo bajonge ukunceda ngedolo elingenalusini okanye ngasemva okuqinileyo, ikrimu inokukhethwa.

Cannabidiol (CBD) Zuza

I-Cannabidiol (i-CBD ngamafutshane) yinto eyenziwa ngokwemvelo i-cannabinoid evela kwisityalo se-cannabis. Yenye yekhulu lama-cannabinoids echongwe kwizityalo ze-hemp. Nangona kunjalo, ngokungafaniyo nesityalo esipheleleyo se-cannabis, i-CBD ayiqulathanga i-THC ejongene nokuxulutywa ngamatye / ukuziva okuphezulu okunikezelwa sisiyobisi sokuzonwabisa. Ikhutshiwe kwiintyatyambo kunye namahlumela esityalo se-hemp, i-CBD icinezelwa kwioyile kwaye iya ithandwa ukunyanga, kunye nokuthintela, uluhlu olubanzi lwemiba yezempilo kumazwe apho intsangu iyeza isemthethweni. Ioyile ye-CBD yomelele kwaye yendalo kuninzi lwee-non-steroidal anti-inflammatory drugs (NSAIDs). Zombini ezi zinto zinokukhutshwa zize ziphuculwe ukuze zisetyenziswe kwi-distillation yendlela emfutshane. Abasebenzisi banokufumana ezi zibonelelo zilandelayo zempilo:

* Ukungalali kunye nexhala

Ukuphazamiseka kwimithambo-luvo

* Lawula ukuxhuzula

Impilo yengqondo kunye nokuphazamiseka okunxulumene neMood

Umgangatho wokulala

* Ulawulo lweentlungu

* Amathambo ezeMpilo

* Iziyobisi kunye nokuxhomekeka

* Ukukhula kancinci kwesifo se-Alzheimer

* Unyango lwezifo zesisu

* Uncedo lubonelela ngoncedo kubantu abane-multiple sclerosis

Cannabidiol (CBD) Imiphumela

Iziphumo ebezingalindelekanga zeCannabidiol (CBD) zibandakanya ukozela, iingxaki zesisu, umlomo owomileyo, ukunciphisa ukutya, isicaphucaphu, kunye nokunxibelelana namanye amayeza.

Cannabidiol (CBDIsicelo

I-Cannabidiol ixhaphake kakhulu kwisifo sokuxhuzula (isifo sokuwa), i-Cannabinoid idityaniswa nenkqubo ye-cytochrome P450 enzyme kwaye inqanda ubukhulu becala ii-enzymes CYP3A4 kunye ne-CYP2D6. I-THC kunye ne-CBD zifunyenwe zinqanda i-CYP1A1, 1A2 kunye ne-1B1 enzymes ngexesha lezifundo ze-vitro. Ukongeza i-CBD isisithinteli esinamandla seCYP2C1P kunye neCYP3A4. Njengokuba uninzi lwezilingo zeklinikhi ziqhubeka, i-CBD ibonisa amandla amangalisayo okuba lonyango olongezelelekileyo kwiimeko ezahlukeneyo zemithambo-luvo. Kufunyenwe ukuba ine-antioxidative, anti-inflammatory, kunye ne-neuroprotective effects. Ibonakalise isithembiso kunyango lweengxaki zemithambo-luvo ezinje ngexhala, iintlungu ezingapheliyo, i-trigeminal neuralgia, isifo se-Crohn, isifo se-Parkinson kunye nokuphazamiseka kwengqondo.

Cannabidiol isishwankathelo

I-Cannabidiol yi-cannabinoid ekhoyo ngomlomo esetyenziselwa ukunyanga abaguli abanesathuthwane esichasayo ngenxa yeLennox-Gastaut okanye iDravet syndrome. I-Cannabidiol inxulunyaniswa nokuphakama kwe-enzyme ye-serum ngexesha lonyango ngakumbi ngamayeza aphezulu kodwa khange idibaniswe namatyala okonzakala kwesibindi kunye ne-jaundice.

isingqiniso

I-Britch SC, i-Babalonis S, i-Walsh SL kunye neCannabidiol: i-pharmacology kunye neethagethi zonyango. I-Psychopharmacology (Berl). 1 uJan; 2021 (238): 1-9. ikhonkco: 28 / s10.1007-00213-020-05712. IINKCUKACHA: 8.

2. I-Samanta D. Cannabidiol: Ukuphononongwa ngokusebenza kweKlinikhi ngokuSebenza kunye noKhuseleko kwi-Epilepsy. 2019 Julayi; 96: 24-29. ikhonkco: 10.1016 / j.pediatrneurol. IINKCUKACHA: 31053391.

3.Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP.Cannabidiol Iziphumo ezibi kunye noTyhefu. Ikhonkco Neuropharmacol. Ngo-2019; 17 (10): 974-989. ikhonkco: 10.2174 / 1570159X17666190603171901.PMID: 31161980.

4. I-Pisanti S, iMalfitano AM njl i-Cannabidiol: Ubume bobugcisa kunye nemiceli mngeni emitsha kwizicelo zonyango. I-Pharmacol Ther. Ngo-2017 uJulayi; 175: 133-150. ikhonkco: 10.1016 / j.pharmthera.PMID: 28232276.

5. I-Burstein S. Cannabidiol (i-CBD) kunye ne-analogs yayo: uphononongo lweziphumo zazo kukudumba. Bioorg Med Chem. 2015 kuMatshi 1; 23 (7): 1377-85. ikhonkco: 10.1016 / j.bmc.2015.01.059. IINKCUKACHA: 25703248.